Central People's Hospital of Zhanjiang
11
4
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
9.1%
1 terminated/withdrawn out of 11 trials
75.0%
-11.5% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
Role: collaborator
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
Role: collaborator
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Role: collaborator
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Role: collaborator
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Role: collaborator
Double-Lumen Tube Intubation in the Lateral Position Versus the Supine Position on First-Attempt Success Rate
Role: collaborator
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
Role: collaborator
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Role: collaborator
Predictive Modeling of Necrotizing Skin Infections in Snakebite Patients
Role: collaborator
Methotrexate in the Treatment of Advanced Knee Osteoarthritis With Effusion-synovitis
Role: collaborator
Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Role: collaborator
All 11 trials loaded